Japanese cedar pollinosis
Conditions
Interventions
After an observation period of 14 days, a placebo is administered orally for 6 days. Montelukast is administered orally for a day after placebo administration. Patients are exposed to cedar poll
Sponsors
Samoncho Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patient with allergic rhinitis, who have specific IgE RAST (cedar pollen) score 2 in the past 2years. 2) Patient who have nasal obstruction, and typical allergic rhinitis symptoms for at least 2 years. 3) Written informed consent is required
Exclusion criteria
Exclusion criteria: 1) Patients with disease which make objective evaluation difficult. *infection disease *nonallergic rhinitis *medicamentosa 2) Anti-allergy drug treatment within two weeks of study entry. 3) Patients who have received immunotherapy. 4) Allergic Rhinitis patients who underwent laser surgery and operation within 6 months. 5) Uncontrolled asthma patients 6) Patients who have the hypersensitivity to study drugs 7) Infectious diseases and mycosis, with no effective therapeutic drug. 8) Pregnant or lactating women and women with possibility of pregnancy. 9) Patients who were judged to be unsuitable for patient enrollment by their doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TNSS(total nasal symptom score) | — |
Countries
Japan
Outcome results
None listed